Phico Therapeutics wins GBP1 million award from Wellcome Trust
PT1.2 is based on a new class of antibacterial proteins called small, acid-soluble spore proteins (SASP) which bind to bacterial DNA resulting in rapid ‘speed of kill’. Phico
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.
SharePlan is an advanced treatment planning solution that enables transfer of treatment plans between TomoTherapy HiArt systems and conventional linear accelerators. The product uses highly sophisticated algorithms to